Characterization of untreated gliomas by magnetic resonance spectroscopic imaging

Neuroimaging Clinics of North America

Volumn 12, Issue 4, 2002, Pages 599-613

  Nelson, Sarah J ^a   McKnight, Tracy R ^a   Henry, Roland G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE;

BRAIN BLOOD VOLUME; BRAIN METABOLISM; CANCER GRADING; CORRELATION COEFFICIENT; DIFFUSION COEFFICIENT; GLIOMA; HEMODYNAMICS; HISTOLOGY; HUMAN; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR NECROSIS; TUMOR VOLUME;

BRAIN; BRAIN CHEMISTRY; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; DIFFUSION MAGNETIC RESONANCE IMAGING; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 0036866840     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-5149(02)00037-0     Document Type: Review

References (90)

1. Daumas-Duport C. Histological grading of gliomas. Current Opinion in Neurology and Neurosurgery 1992;5:924-31.
2. Kleihues P, Burger PC, Scheithauer BW, et al. Histological Typing of Tumours of the Central Nervous System. 2nd Edition. Berlin, New York: Springer-Verlag; 1993. p. 112.
3. Russell DS, Rubenstein LJ. Pathology of Tumors of the Nervous System. 5th Edition. London: Williams and Wilkins; 1989.
4. Aldape K, Simmons ML, Davis RL, et al. Discrepancies in diagnoses of neuroepithelial neoplasms: The San Francisco Bay Area Adult Glioma Study. Cancer 2000;88:2342-9.
5. Dean BL, Drayer BP, Bird CR, et al. Gliomas: Classification with MR imaging. Radiology 1990;174:411-5.
6. Earnest FT, Kelly PJ, Scheithaurer BW, et al. Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823-7.
7. Kurki T, Lundbom N, Kalimo H, et al. MR classification of brain gliomas: Value of magnetization transfer and conventional imaging. Magn Reson Imaging 1995;13:501-11.
8. Yuh WT, Nguyen HD, Tali ET, et al. Delineation of gliomas with various doses of MR contrast material. American Journal of Neuroradiology 1994;15:983-9.
9. Di Chiro G. Positron emission tomography using F-18-fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360-71.
10. Janus TJ, Kim EE, Tilburq R, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540-8.
11. Chang L, McBride D, Miller BL, et al. Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995;5:157-63.
12. Usenius JP, Kauppinen RA, Vainio PA, et al. Quantitative metabolite patterns of human brain tumors: Detection by 1H NMR spectroscopy in vivo and in vitro. J Comput Assist Tomogr 1994;18:705-13.
13. Usenius JP, Vainio P, Hemesniemi J, et al. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem 1994;63:1538-43.
14. Cheng LL, Ma MJ, Becerra L, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 1997;94:6408-13.
15. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
16. Heesters MA, Kaudstaal J, Go KG, et al. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value. J Neurooncol 1999;44:255-66.
17. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: A multicenter study. J Neurosurg 1996;84:449-58.
18. Segebarth CM, Balériaux DF, Luyten PR, et al. Detection of metabolic heterogeneity of human intracranial tumors in vivo by 1H NMR spectroscopic imaging. Magn Reson Med 1990;13:62-76.
19. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. American Journal of Neuroradiology 1996;17:737-47.
20. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: Clinical relevance. Radiology 1992;185:675-86.
21. Luyten PR, Marien AJ, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990;176:791-9.
22. Kugel H, Heindel W, Emestus RI, et al. Human brain tumors: Spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992;183:701-9.
23. Dowling C, Ballen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. American Journal of Neuroradiology 2001;22:604-12 [comment in: American Journal of Neuroradiology 2001;22:597-8].
24. McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 2001;13:167-77.
25. Nelson SJ, Vigneron DB, Star-Lack J, et al. High spatial resolution and speed in MRSI. NMR Biomed 1997;10:411-22.
26. Nelson SJ, Vigneron DB, Dillon WP. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 1999;12:123-38.
27. Duyn JH, Gillen J, Sobering G, et al. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277-82.
28. Duyn JH, Moonen CT. Fast proton spectroscopic imaging of human brain using multiple spin-echoes. Magn Reson Med 1993;30:409-14.
29. Spielman DM, Pauly JM, Macovski A, et al. Lipid-suppressed single- and multisection proton spectroscopic imaging of the human brain. J Magn Reson Imaging 1992;2:253-62.
30. Adalsteinsson E, Irarrazabal P, Spielman DM, et al. Three-dimensional spectroscopic imaging with time-varying gradients. Magn Reson Med 1995;33:461-6.
31. Posse S, DeCarli C, Le Bihan D. Three-dimensional echo-planar MR spectroscopic imaging at short echo times in the human brain. Radiology 1994;192:733-8.
32. Posse S, Tedeschi G, Risinger R, et al. High speed 1H spectroscopic imaging in human brain by echo planar spatial-spectral encoding. Magn Reson Med 1995;33:34-40.
33. Star-Lack J, Nelson SJ, Kurthanewicz J, et al. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-21.
34. Star-Lack J, Spielman D, Adalsteinsson E, et al. In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors. J Magn Reson 1998;133:243-54.
35. Star-Lack J, Vigneron DB, Pauly J, et al. Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging 1997;7:745-57.
36. Tran TK, Vigneron DB, Sailasuta N, et al. Very selective suppression pulses for clinical MRSI studies of brain and prostate cancer. Magn Reson Med 2000;43:23-33.
37. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med 2001;46:228-39.
38. Barkhuijsen H, deBeer R, Bovee WM, et al. Application of linear prediction and singular value decomposition (LPSVD) to determine NMR frequencies and intensifies from the FID. Magn Reson Med 1985;2:86-9.
39. Spielman D, Webb P, Macovski A. A statistical framework for in vivo spectroscopic imaging. J Magn Reson 1988;79:66-77.
40. van der Veen JW, deBeer R, Luyten PR, et al. Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988;6:92-8.
41. Nelson SJ, Brown TR. A new method for automatic quantification of 1-D spectra with low signal to noise ratio. J Magn Reson 1987;75:229-43.
42. Nelson SJ, Brown TR. A study of the accuracy of quantification which can be obtained from 1-D NMR spectra using the PIQABLE algorithm. J Magn Reson 1989;84:95-109.
43. Bretthorst GL, Kotyk JJ, Ackerman JJ. 31P NMR Bayesian spectral analysis of rat brain in vivo. Magn Reson Med 1989;9:282-7.
44. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-9.
45. Spielman D, Webb P, Macovski A. Water referencing for spectroscopic imaging. Magn Reson Med 1989;12:38-49.
46. Andersson JL, Sundin A, Valind S. A method for co-registration of PET and MR brain images. J Nucl Med 1995;36:1307-15.
47. Collins DL, Neclin P, Peters TM, et al. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994;18:192-205.
48. Dhawan AP, Arata L. Knowledge-based multi-modality three-dimensional image analysis of the brain. American Journal of Physiologic Imaging 1992;7:210-9.
49. Levin DN, Pelizzari CA, Chen GT, et al. Retrospective geometric correlation of MR, CT, and PET images. Radiology 1988;169:817-23.
50. Pelizzari CA, Chen GT, Spelbring DR, et al. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. J Comput Assist Tomogr 1989;13:20-6.
51. Strother SC, Anderson JR, Xu XL, et al. Quantitative comparisons of image registration techniques based on high-resolution MRI of the brain. J Comput Assist Tomogr 1994;18:954-62.
52. Wang C, Pahl JJ, Hogue RE. A method for co-registering three-dimensional multi-modality brain images. Comput Methods Programs Biomed 1994;44:131-40.
53. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536-46.
54. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: Assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990;176:211-20.
55. Fisel CR, Ackerman JL, Buicton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: Numerical simulations and applications to cerebral physiology. Magn Reson Med 1991;17:336-47.
56. Rosen BR, Belliveau JW, Chien D. Perfusion imaging by nuclear magnetic resonance. Magn Reson Q 1989;5:263-81.
57. Henry RG, Vigneron DB, Fischbein NJ, et al. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. American Journal of Neuroradiology 2000;21:357-66.
58. nd Annual Meeting of the Society for Magnetic Resonance in Medicine, Aug 6-12, 1994, San Francisco (CA);(1) p.279 [abstract].
59. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. American Journal of Neuroradiology 2000;21:891-9.
60. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
61. Roberts HC, Roberts TP, Bollen AW, et al. Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade tumor labeling index: A study in human brain tumors. Acad Radiol 2001;8:384-91.
62. Brunberg JA, Chenevert TL, Mckeever PE, et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: Correlation with structural alteration in gliomas of the cerebral hemispheres. American Journal of Neuroradiology 1995;16:361-71.
63. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53-60.
64. Tien RD, Felsburg GJ, Friedman H, et al. MR imaging of high-grade cerebral gliomas: Value of diffusion-weighted echoplanar pulse sequences. American Journal of Roentgenology 1994;162:671-7.
65. Basser PJ, Pierpaoli C. A simplified method to measure the diffusion tensor from seven MR images. Magn Reson Med 1998;39:928-34.
66. De Coene B, Hajnal JV, Gatehouse P, et al. MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. American Journal of Neuroradiology 1992;13:1555-64.
67. Rydberg JN, Hammond CA, Grimm RC, et al. Initial clinical experience in MR imaging of the brain with a fast fluid-attenuated inversion-recovery pulse sequence. Radiology 1994;193:173-80.
68. Catalaa I, Henry WP, Dillion E, et al. Perfusion, diffusion, and spectroscopy values in newly diagnosed cerebral gliomas. Radiology, submitted for publication.
69. Knopp EA, et al. Human brain tumors: Spectral pattems detected with localized H-1 MR spectroscopy. Radiology 1999;211:791-8.
70. Pirzkall A, Nelson SI, McKnight TR, et al. Metabolic imaging of low-grade gliomas with 3D MR spectroscopy. Int J Rad Onc Biol Phys 2002;53(5):254-64.
71. Li X, Pirzkall A, Ying L, et al. Analysis of spatial characteristics of the metabolic abnormalities for newly diagnosed glioma patients. J Magn Reson Imaging 2002;16(3):229-37.
72. Falini A, Calabrese G, Origgi D, et al. Proton magnetic resonance spectroscopy and intracranial tumours: Clinical perspectives. J Neurol 1996;243:706-14.
73. Gupta R, Cloughesy T, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000 Dec;50(3):215-26.
74. Preul MC, Caramanas Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-5.
75. Somorjai RL, Dolenky B, Nikulin AK, et al. Classification of 1H MR spectra of human brain neoplasms: The influence of preprocessing and computerized consensus diagnosis on classification accuracy. J Magn Reson Imaging 1996;6:437-44.
76. Arnold DL, Shoubridge EA, Villemure JG, et al. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed 1990;3:184-9.
77. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: Initial experience in patients with cerebral tumors [see comments]. Radiology 1989;172:541-8.
78. Gill SS, Thomas DG, Van Bruggan N, et al. Proton MR spectroscopy of intracranial tumours: In vivo and in vitro studies. J Comput Assist Tomogr 1990;14:497-504.
79. Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. American Journal of Neuroradiology 1995;16:1593-603.
80. Butzen J, Kapsalaki EZ, Gotsis SD, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: The limits of accuracy with a logistic regression model. American Journal of Neuroradiology 2000;21:1231-9.
81. Fountas KN, Kapsalaki EZ, Gotsis SD, et al. In vivo proton magnetic resonance spectroscopy of brain tumors. Stereotact Funct Neurosurg 2000;74:83-94.
82. Meyerand ME, Pipas JM, Mamourian A, et al. Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy [see comments]. American Journal of Neuroradiology 1999;20:117-23.
83. Hagberg G, Burlina AP, Mader I, et al. In vivo proton MR spectroscopy of human gliomas: Definition of metabolic coordinates for multi-dimensional classification. Magn Reson Med 1995;34:242-52.
84. Underwood J, Tate AR, Luckin R, et al. A prototype decision support system for MR spectroscopy-assisted diagnosis of brain tumours. Medinfo 2001;10:561-5.
85. Castillo M, Smith JK, Kwock L. Correlation of myoinositol levels and grading of cerebral astrocytomas. American Journal of Neuroradiology 2000;21:1645-9.
86. Furuya S, Naruse S, Ide M, et al. Evaluation of metabolic heterogeneity in brain tumors using 1H-chemical shift imaging method. NMR Biomed 1997;10:25-30.
87. McKnight TR, von dem Bussche M, Vigneron DB, et al. Histopathological validation of a 3D-MRSI Cho-NAA index as a predictor of tumor presence. J Neurosurg 2002;97:794-802.
88. Sabatier J, Ibarrola D, Maler-Martino I, et al. Brain tumors: Interest of magnetic resonance spectroscopy for the diagnosis and the prognosis. Rev Neurol (Paris) 2001;157:858-62.
89. Tate AR, Griffiths JR, Martinez-Perez I, et al. Towards a method for automated classification of 1H MRS spectra from brain tumours. NMR Biomed 1998;11:177-91.
90. Carapella CM, Carpinelli G, Knijn A, et al. Potential role of in vitro 1H magnetic resonance spectroscopy in the definition of malignancy grading of human neuroepithelial brain tumours. Acta Neurochir Suppl (Wien) 1997;68:127-32.